Anapen 300®, Anapen 500® and Anapen 150 Junior® (Anapen Junior) adrenaline (epinephrine) autoinjectors have been approved by the Therapeutic Goods Administration (TGA) for the treatment of anaphylaxis (severe allergic reactions). 

The Pharmaceutical Benefits Advisory Committee (PBAC) has recommended the General Schedule Authority Required Pharmaceutical Benefits Scheme (PBS) listing of Anapen 300®, Anapen 500® and Anapen 150 Junior®. The Public Summary Documents from the November 2020 PBAC meeting are now available.

It is expected that Anapen 300®, Anapen 500® and Anapen 150 Junior® will be available in Australia on the PBS in September 2021. 

In preparation for the updating of ASCIA resources and e-training courses by July 2021, ASCIA has developed:

• ASCIA Action Plan for Anaphylaxis - Anapen version www.allergy.org.au/hp/anaphylaxis/ascia-action-plan-for-anaphylaxis
• How to give Anapen www.allergy.org.au/hp/anaphylaxis#aj2